Takeda reports phase III results for alogliptin

Takeda has announced the publication of phase III study results for alogliptin at the scientific sessions of the American Diabetes Association.

The results from the five pivotal studies showed that alogliptin demonstrated significant blood sugar reductions when administered as a monotherapy and in four add-on therapy studies.

In the studies, use of alogliptin resulted in reductions in haemoglobin A1c (HbA1c) compared to placebo when used alone or in conjunciton with insulin, metformin, sulfonylureas or thiazolidinediones.

Alogliptin is a highly-selective dipeptidyl peptidase-4 inhibitor currently being investigated as an orally-administered treatment for type 2 diabetes.

Richard Pratley, director of the Diabetes and Metabolism Translational Medicine Unit at the University of Vermont College of Medicine, said: “These clinical data show that alogliptin effectively reduces blood sugar in patients, alone or when used in combination with existing oral anti-diabetic treatments as well as insulin, increasing the range of treatment options for patients.”

He added that almost half of the patients with type 2 diabetes have not met the target HbA1c goal of the American Diabetes Association of less than seven per cent.

In January 2008, Takeda Pharmaceutical announced major progress with the submission of alogliptin to regulatory authorities as a treatment for type 2 diabetes.